Madrigal Pharmaceuticals (MDGL) Liabilities and Shareholders Equity (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $1.2 billion in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $1.2 billion, up 23.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.9 billion (up 15.5% YoY), and the FY2025 annual result was $1.3 billion, up 20.85% from the prior year.
• Liabilities and Shareholders Equity slipped to $1.2 billion in Q1 2026 per MDGL's latest filing, from $1.3 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $1.4 billion in Q3 2025 and troughed at $158.6 million in Q3 2022.
• A 5-year average of $743.1 million and a median of $996.6 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity tumbled 47.93% in 2022, then jumped 351.02% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $362.6 million in 2022, then surged by 76.67% to $640.5 million in 2023, then surged by 62.71% to $1.0 billion in 2024, then rose by 20.85% to $1.3 billion in 2025, then declined by 2.56% to $1.2 billion in 2026.
• Business Quant data shows MDGL's Liabilities and Shareholders Equity at $1.2 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.4 billion in Q3 2025.